Lv11
40 积分 2026-02-24 加入
[Consensus on recurrence risk and clinical management of HR+/HER-2- early breast cancer (2025 edition)]
6小时前
待确认
Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial
1个月前
已完结
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
1个月前
已完结
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
1个月前
已关闭
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials
2个月前
已完结
Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase IIa trial
2个月前
已完结
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression
2个月前
已关闭
De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial
3个月前
已完结
Fertility Preservation in People With Cancer
3个月前
已关闭
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
3个月前
已完结
皖公网安备34019202002308
